Skip to content
Clinical Trials – home
DenmarkBack to Denmark

Clinical trials in Holbæk – page 5

621 clinical trials in Holbæk, Denmark across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

DenmarkOur site in DenmarkKliniske-Forsoeg.dk(opens in a new tab)
Holbæk at a glance
621
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

621 trials in Holbæk

Open in trial search

Study of AZD6234 (lenbelintide) Added to Incretin Therapy in Adults with Obesity or Overweight and a Weight‑Related Comorbidity, With or Without Type 2 Diabetes

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:AZD6234
  • Sponsor:AstraZeneca AB

Study of Rinatabart Sesutecan with glatiramer acetate in patients with advanced gastrointestinal cancers

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Glatiramer Acetate
  • Sponsor:Genmab A/S

First‑line Study of RMC‑9805 with Investigator’s Choice Chemotherapy Drug Combination vs Chemotherapy Alone in Patients with Metastatic KRAS G12D‑Mutated Pancreatic Adenocarcinoma

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Zoldonrasib
  • Sponsor:Revolution Medicines Inc.

COVID-19+1

Recruiting

Effectiveness of mCOMBRIAX vaccine compared with high‑dose influenza vaccine and mRNA‑1273 in adults ≥65 years for prevention of influenza and COVID‑19

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:65+ years · Healthy volunteers
  • Substances:CX-038869
  • Sponsor:Gentofte Hospital

Efficacy and Safety of JNJ-78934804 (guselkumab and golimumab) in Adults with Moderately to Severely Active Ulcerative Colitis

InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Golimumab
  • Sponsor:Janssen Cilag International

Randomized trial of elecoglipron with dapagliflozin versus placebo in adults with type 2 diabetes mellitus and impaired renal function

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

Study of AZD0486 plus rituximab versus standard chemotherapy drug combination in previously untreated follicular lymphoma patients

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:AstraZeneca AB

Study of precemtabart tocentecan alone or in drug combination versus standard therapy in previously treated metastatic colorectal cancer patients

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Merck Healthcare KGaA

Osteosarcoma

Recruiting

Cabozantinib Maintenance Therapy vs Best Supportive Care in Osteosarcoma Patients in Complete Remission or with Residual Disease after First‑Line Chemotherapy

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cabozantinib
  • Sponsor:Institut Gustave Roussy

Cevostamab, Pomalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 1‑3 Lines of Therapy

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:F. Hoffmann-La Roche AG

Efficacy and safety of lunsekimig in adults with inadequately controlled eosinophilic COPD: a randomized, double‑blind, placebo‑controlled trial

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Lunsekimig
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Rinatabart Sesutecan plus bevacizumab vs standard care as maintenance for recurrent platinum‑sensitive ovarian cancer after second‑line chemotherapy

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Genmab A/S

Other cities in Denmark

The busiest research cities in the country

All 45 cities in Denmark

Clinical research in Holbæk

What the registry says about research in the country

01 Cardiovascular Research

Groundbreaking studies focusing on heart failure prevention and innovative treatments for atrial fibrillation. Multiple trials are evaluating new therapeutic combinations and medications for improved patient outcomes.

  • Heart Failure Management
  • Stroke Prevention
  • Cardiac Arrest Treatment

Research includes novel approaches using baxdrostat and dapagliflozin combinations for heart failure risk reduction.

02 Kidney Disease Studies

Comprehensive research into chronic kidney disease treatments, particularly focusing on patients with concurrent hypertension. Studies examine innovative therapeutic approaches for non-diabetic kidney disease.

  • CKD Progression
  • Hemodialysis Treatments
  • Renal Function Protection

Trials investigate combined therapies to slow disease progression and improve patient outcomes.

03 Metabolic Disorders

Innovative trials addressing obesity management in different age groups, with special attention to adolescent populations. Studies also focus on diabetes treatment approaches.

  • Weight Management Therapies
  • Type 1 & 2 Diabetes
  • Metabolic Interventions

Research includes novel treatments with semaglutide for weight management in young populations.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.